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The  cellular  prion  protein  (PrPC)  is an  ubiquitously  expressed  glycoprotein  that  is most  abundant  in  the
central  nervous  system.  It is  thought  to  play  a role  in  many  cellular  processes,  including  neuroprotection,
but  may  also  contribute  to  Alzheimer’s  disease  and  some  cancers.  However,  it is best known  for  its central
role  in  the  prion  diseases,  such  as  Creutzfeldt-Jakob  disease  (CJD),  bovine  spongiform  encephalopathy
(BSE),  and  scrapie.  These  protein  misfolding  diseases  can  be sporadic,  acquired,  or genetic  and  are  caused
by refolding  of  endogenous  PrPC into  a beta sheet-rich,  pathogenic  form,  PrPSc. Once  prions  are  present
in  the  central  nervous  system,  they  increase  and spread  during  a long  incubation  period  that  is  followed
by  a relatively  short  clinical  disease  phase,  ending  in death.  PrP  molecules  can  be  broadly  categorized
as  either  ‘good’  (cellular)  PrPC or ‘bad’  (scrapie  prion-type)  PrPSc, but both  populations  are  heteroge-
neous  and  different  forms  of PrPC may  inﬂuence  various  cellular  activities.  Both  PrPC and  PrPSc are
localized  predominantly  at the  cell  surface,  with  the  C-terminus  attached  to  the plasma  membrane  via
Ca  glycosyl-phosphatidylinositol  (GPI)  anchor  and  both  can  exist  in cleaved  forms.  PrP also  has  cytosolic
and  transmembrane  forms,  and  PrPSc is  known  to  exist  in  a variety  of  conformations  and  aggregation
states.  Here, we  discuss  the  roles  of different  PrP  isoforms  in sickness  and  in  health,  and  show  the  sub-
cellular  distributions  of  several  forms  of  PrP  that  are particularly  relevant  for PrPC to  PrPSc conversion
and  prion-induced  pathology  in the  hippocampus.
©  2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. PrPC-in health
.1. Cell surface PrPC may inﬂuence many cellular activities
Mature PrPC is a secreted, 208–209 amino acid protein, tethered
o the cell membrane with a GPI anchor (Stahl et al., 1993). PrPC
as an alpha helix-rich C-terminal globular domain, containing
wo asparagine-linked glycosylation sites and an intramolecular
isulphide bond. It has a hydrophobic central region and a
elatively unstructured N-terminal domain, containing ﬁve repeats
Abbreviations: BSE, bovine spongiform encephalopathy; cAMP, cyclic adenosine
onophosphate; CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal ﬂuid; EM,  elec-
ron microscopy; ER, endoplasmic reticulum; ERK1/2, extracellular signal-regulated
rotein kinases 1 and 2; GPI, glycosyl-phosphatidylinositol; PRNP, human prion pro-
ein gene; PrP, prion protein; PrPC, cellular form of PrP; PrPSc, prion form of PrP; SDS
AGE, sodium dodecylsulfate polyacrylamide gel electrophoresis; UPR, unfolded
rotein response.
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∗∗ Corresponding author. Tel.: +17802481712.
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H. Wille).
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168-1702/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
of a copper-binding octapeptide (reviewed in Colby and Prusiner,
2011) (Fig. 1b).
In normal tissues, PrPC is localized predominantly on
plasma membranes, as illustrated by cryo-immunogold electron
microscopy (EM) of brain (Godsave et al., 2008; Mironov et al.,
2003) (Fig. 2). Here, it appears to follow the standard biosyn-
thetic trafﬁcking pathway for GPI-anchored glycoproteins and is
then transported to axons and dendrites in the neuropil, with no
apparent preferential localization at synapses. It is internalized via
endosomes and recycled back to the plasma membrane and can
be detected by cryo-immunogold electron microscopy in small
diameter vesicles resembling early endocytic or recycling vesi-
cles. It is also found, less frequently, in late endosomal structures
(Godsave et al., 2008; Mironov et al., 2003), where degradation of
membrane-associated PrPC occurs. For a review of PrPC trafﬁcking,
see Campana et al. (2005).
GPI-anchored PrPC is often associated with cholesterol- and
sphingolipid-rich membrane ‘rafts’ which can serve as organizing
centres for signalling complexes that may inﬂuence a variety of
cellular activities (reviewed in Campana et al., 2005). GPI-anchored
PrPC does not span the membrane and cannot transduce signals into
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
S.F. Godsave et al. / Virus Resea
Fig. 1. PrPC forms described in the text. Translation of the human PRNP gene results
in  a pre-pro form with N-terminal signal sequence for secretion (N-SS, residues
1–22) and signal sequence for GPI anchor addition (GPI-SS, residues 232–253) (a).
The N-SS and/or GPI-SS are retained in some post-translationally modiﬁed forms of
PrP (f–i). Octarepeat, metal-binding sites are shown as grey rectangles (OR, residues
59–90), and the hydrophobic region (HR, residues 112–133) as a black rectangle.
The presence of a GPI anchor is illustrated in lower images by a zigzag line and a
membrane by a large grey rectangle. In mature PrPC there is a single disulphide
bond between residues 179 and 214 and glycosylation sites at residues 181 and
197, which may  be variably ﬁlled. Non-translocated PrP and pro-PrP are reported
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tructure. References are provided in the text.
he cytosol, but it has many binding partners and has been proposed
o play a role in the assembly of signalling complexes. Among its
ell surface binding partners are stress inducible protein 1 (STI1)
Lopes et al., 2005; Zanata et al., 2002), the 37 kDa Laminin Recep-
or Precursor/67 kDa Laminin Receptor (37LRP/67LR) (Gauczynski
t al., 2001), neural cell adhesion molecule (NCAM) (Santuccione
t al., 2005; Schmitt-Ulms et al., 2001), laminin (Graner et al., 2000)
nd vitronectin (Hajj et al., 2007), as well as glycosaminoglycans
Caughey et al., 1994; Pan et al., 2002) and copper (Brown et al.,
997; Jones et al., 2004) (reviewed in Linden et al., 2012; Martins
t al., 2010). Several studies have further indicated that PrPC is
nvolved in signalling via the cAMP-dependent protein kinase A and
RK1/2 pathways, thereby inﬂuencing neural survival and neuri-
ogenesis, and possibly memory formation (reviewed in Didonna,
013; Martins et al., 2010). PrPC is also reported to regulate the
roliferation of haematopoietic stem cells, human embryonic stem
ells and neural precursors (Lee and Baskakov, 2010; Santos et al.,
011; Steele et al., 2007c).
A major function of PrPC appears to be protection of neurons
rom oxidative stress and apoptosis. Mice in which the prion gene
as been knocked out are viable and resistant to prion infection
Bueler et al., 1993), but have subtle abnormalities consistent with
 neuroprotective function for PrPC, including enhanced suscepti-
ility to ischaemia. Other reported effects include abnormalities in
leep, brain copper levels, neuronal excitability and memory (Steele
t al., 2007c). In zebraﬁsh, which have two PrP genes, PrP-2 appears
o have similar functions to mammalian PrPC (Fleisch et al., 2013).
y contrast, loss of PrP-1 function is embryonic lethal, causing
efects in cell-to-cell adhesion and gastrulation arrest (Malaga-
rillo et al., 2009).
.2. Release of cytoprotective fragments by PrPC cleavage and
hedding
A physiological cleavage of membrane-associated PrPC after
mino acid 110 or 111 (humans) releases a soluble N-terminalrch 207 (2015) 136–145 137
fragment (N1) and creates a GPI-anchored C-terminal fragment
(C1) (Chen et al., 1995; Harris et al., 1993) (Fig. 1c). This so-called
alpha cleavage occurs adjacent to the central hydrophobic region
of PrP that is necessary for PrPC to PrPSc conversion, and transgenic
mice expressing only the C1 region of PrP are resistant to infectious
prion disease (Lewis et al., 2009; Westergard et al., 2011). Proteoly-
tic cleavage may  be a mechanism for regulating PrPC activity, since
the N-terminal portion contains the binding sites for a variety of
ligands (Martins et al., 2010). Cytoprotective activities have been
described for N1. Addition of recombinant N1 to cultured corti-
cal neurons reduced staurosporine-induced caspase-3 activation
in a p53-depedent manner and N1 was also able to protect cells
from amyloid -induced neurotoxicity (Guillot-Sestier et al., 2009,
2012). The function of C1 seems less clear (see Section 2.3).
Another type of cleavage, termed beta cleavage, has been found
to occur at around amino acid 90 of PrPC (Mange et al., 2004)
(Fig. 1d). This can be mediated by reactive oxygen species and is
associated with greater cell viability in response to oxidative stress
(McMahon et al., 2001; Watt et al., 2005). PrPSc can undergo cleav-
age at a similar position (see Section 4.1).
Cleavage of PrPC close to the GPI anchor has also been described,
causing the release of soluble, almost full length PrPC from the
membrane (Borchelt et al., 1993; Stahl et al., 1990; Wik  et al., 2012)
(Fig. 1e). This form can be found in cerebrospinal ﬂuid (CSF) and
blood and might act as a soluble trophic factor. ‘Shedding’ may
also be a mechanism for regulating PrP levels on the cell surface
(Borchelt et al., 1993; Wik  et al., 2012; reviewed in Altmeppen et al.,
2012).
1.3. Cytosolic PrP and protection against apoptosis
PrPC may  enter the cytosol as a result of retro-translocation from
the ER (Ashok and Hegde, 2008; Yedidia et al., 2001) (Fig. 1f), and
it has been reported that this form of PrPC is able to protect human
primary neurons from Bax-mediated apoptosis. Similar cytopro-
tection has also been found for other cell types, but is not universal
(Lin et al., 2008; Roucou et al., 2003, 2004). Cytosolic PrPC has
been reported in subpopulations of neurons in normal mouse brain
although its signiﬁcance in these cells is still unclear (Mironov et al.,
2003).
PrPC may  also enter the cytosol by avoiding translocation into
the endoplasmic reticulum (ER) (Drisaldi et al., 2003; Orsi et al.,
2006) (Fig. 1g). A small proportion of newly synthesized PrPC may
normally ‘leak’ into the cytosol in this way, due to inherent inefﬁ-
ciencies of the signal sequence for secretion (Levine et al., 2005).
There are ER stress response elements in the gene encoding PrP
(PRNP) (Dery et al., 2013) and unglycosylated, cytosolic PrPC is
increased by ER stress (Orsi et al., 2006). This may  be due to pre-
emptive quality control preventing translocation of newly formed
PrPC molecules into the ER (Rane et al., 2008). PrPC that enters the
cytosol is normally rapidly degraded, but if this occurs inefﬁciently,
deleterious aggregates may  form (Section 2.4).
An alternative, shorter transcript from the prion gene with a
completely different amino acid sequence also exists (termed Alt-
PrP). This is constitutively co-expressed with PrPC, localizes to
mitochondria and is up-regulated by ER stress (Vanderperre et al.,
2011). Its function remains to be established.
2. PrPC – in sickness
Various PrPC-dependent activities have been described, some-
times apparently conﬂicting, due to differences in binding partners
and/or in post-translational processing and trafﬁcking, and some
of its activities can be deleterious. For example, PrPC is undoubt-
edly critical for prion disease, not only as a substrate for prion
138 S.F. Godsave et al. / Virus Research 207 (2015) 136–145
Fig. 2. Cryo-immunogold EM labelling of PrP in the hippocampus Stratum oriens of uninfected and RML  prion-infected FVB mice. Note that membranes appear white using
this  method. Clinical disease stage is reached in the prion-infected mice at approximately 120 dpi. F4-31 labelling of PrPC in uninfected (Uninf, A, and B) and late preclinical
stage  (104 dpi) prion-infected hippocampus (C). No increase in PrPC labelling was  seen in prion-infected hippocampus. PrPC and PrPSc labelling by Saf32 (D–G) and R2
(H–J)  in prion-infected hippocampus. Clusters of gold particles indicate sites of PrPSc accumulation. These are found on the cell surface (D, F, and H) or on plasma membrane
invaginations (E, G, and I). Clustered R2 labelling can also be found on vesicles resembling early or recycling endosomes (J). Closed arrows indicate plasma membrane labelling;
arrowheads point to gold particles on early endocytic/recycling vesicles (A, C, H, and J) or to labelled plasma membrane invaginations (E, G, and I); open arrows indicate
extracellular label. In panel B, the open arrowhead (<) indicates a labelled synaptic junction. Asterisk in panel C indicates a gold particle associated with a multivesicular
body.  Abbreviations: ax, axon; den; dendrite; dpi, days post-inoculation; m,  mitochondrion; my,  myelin; pyr, pyramidal cell body; sb, synaptic bouton. Panels for this ﬁgure
were  taken from (Godsave et al., 2008, 2013). Bars represent 200 nm.
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eplication (Bueler et al., 1993) (reviewed in Colby and Prusiner,
011 and see Section 4.1), but also as a trigger for the neurotoxic
ffects that are caused by prions and other molecules.
.1. Cell surface PrPC and cytotoxicity
PrPC resides mainly on the cell surface and is present at sim-
lar levels in murine hippocampus after prion infection (Godsave
t al., 2008) (Fig. 2). Build-up of PrPSc in the prion-infected central
ervous system results in impaired neurophysiological function,
nd ultimately in apoptosis. Oligomeric, -sheet-rich forms of PrP
ay  be neurotoxic independent of PrPC expression under some
onditions (Novitskaya et al., 2006; Simoneau et al., 2007). How-
ver, there is also ample evidence that PrPC is essential for prion
athology in vivo. Replication and release of PrPSc by implants
f PrPC-expressing, prion-infected brain tissue failed to elicit
etectable pathology in host PrP knockout brains (Brandner et al.,
996). In transgenic mice in which neuronal PrPC was depleted
uring prion infection, extra-neuronal PrPSc accumulation contin-
ed, but without neuronal loss or clinical disease (Mallucci et al.,
003). Furthermore, PrPSc replicated efﬁciently after inoculation
f prions into transgenic mice expressing GPI-anchorless PrP, but
igns of neurodegeneration only appeared after an extended incu-
ation period and only if PrP expression levels were sufﬁciently
igh (Chesebro et al., 2010).
The PrPC-dependent neurotoxicity induced by PrPSc can occur
ndependently of prion replication,  and can also be elicited by
ther beta sheet-rich protein oligomers, including amyloid 
Resenberger et al., 2011). A large number of studies have impli-
ated PrPC as a receptor for amyloid  oligomers in Alzheimer’s
isease (e.g. Laurén et al., 2009; Schwarze-Eicker et al., 2005) and
inding of amyloid  to membrane-associated PrPC has further
een found to trigger signalling via fyn, and cause hyperphosphory-
ation of tau, accompanied by synaptic and cognitive impairments
Larson et al., 2012).
A variety of anti-PrP antibodies were found to induce toxicity
pon binding to the globular domain of PrPC, particularly the 1 and
3 helices (Sonati et al., 2013). Surprisingly, this toxicity required
he presence of the N-terminal octapeptide repeats to transmit the
oxic signal from the globular domain to a superoxide-producing
ffector, presumably NOX2. The conformation of the octapeptide
epeats is modulated by the binding of copper ions and affects their
iological effects (Lau et al., 2015).
PrPC is able to regulate the expression and activity of p53 in
everal cell types and it increases the susceptibility of primary cul-
ured neurons to staurosporine-induced apoptosis, mediated via
aspase 3 activation (Paitel et al., 2004). PrPC can also activate cas-
ases 9 and 3 and PKC in response to ER stress to induce cell death
Anantharam et al., 2008). However, PrP subcellular localization
as not investigated in these studies, raising the possibility that
R stress-induced cytosolic PrPC is responsible for this activity (see
ections 1.3 and 2.4).
.2. Abnormally folded PrP in familial prion disease
About 10–15% of human prion disease cases have a genetic ori-
in, with more than forty different mutations of the human PrP
ene, PRNP, associated with the three heritable forms of prion
isease. These are classiﬁed according to the clinical symptoms
s genetic (or familial) CJD, Gerstmann–Sträussler–Scheinker syn-
rome or fatal familial insomnia. Disease-associated mutations
re generally of two types: point mutations that result either in
n amino acid change or a premature stop codon; insertions or
eletions that result in a changed number of octarepeats in the N-
erminal region. Additionally, polymorphisms, especially of codon
29, are able to inﬂuence disease susceptibility and type (reviewedrch 207 (2015) 136–145 139
in Capellari et al., 2011; Colby and Prusiner, 2011). Various mech-
anisms may  be responsible for the development of genetic prion
disease, including the spontaneous conversion of mutant PrPC into
PrPSc. Most disease-associated point mutations are in the globular
C-terminal portion of PrP and many are associated with decreased
conformational stability of the polypeptide chain, or increased
stability of an intermediate that might favour PrPSc production.
Studies of recombinant PrP have indicated that several mutants
fall into this group (e.g. D178N and V210I, but not E200K) (Apetri
et al., 2004; Riek et al., 1998). However, changes in surface electro-
static potential were found for E200K, which are likely to affect its
protein–protein interactions (Zhang et al., 2000).
Mutations also affect PrPC metabolism and trafﬁcking in many
cases. Unusual PrPSc glycoform ratios have been found in sam-
ples from some patients with point mutations. For example, P102L,
D178N, E200K all resulted in over-representation of diglycosylated
PrPSc, and it was  proposed that certain PrPSc assembly states may
be favoured in these cases (reviewed in Capellari et al., 2011; van
der Kamp and Daggett, 2009).
Insertion of additional octapeptide repeats into the N-terminal
domain of PrP is a risk factor for prion disease, with higher numbers
of repeats more likely to lead to disease, with earlier presentation
and shorter duration. Furthermore, homozygosity for methionine
at codon 129, a risk factor for sporadic CJD, was  also associated
with increased penetrance and earlier prion disease onset (Croes
et al., 2004; Kaski et al., 2011). Octarepeat insertions do not appear
to affect the structure of the globular portion of the molecule.
However, insertion of additional octarepeats into a truncated PrP
molecule (residues 23–144) that can form amyloid under non-
denaturing conditions increased its rate of aggregation and amyloid
formation (Moore et al., 2006). Increasing the numbers of octare-
peats in full length, glycosylated PrP was also able to enhance
binding between PrPC and PrPSc molecules. Although it is not clear
how initial exposure to PrPSc might occur in such cases, it might
provide an explanation for an increased likelihood of disease fol-
lowing a low probability initiation event (Moore et al., 2006).
Interestingly, deletion of two  octarepeats can also result in prion
disease, although as yet the mechanism is unclear (Beck et al., 2001;
Capellari et al., 2002).
The mutation A117V lies in the hydrophobic region of PrP. This
stretch of amino acids spans the membrane in two  transmembrane
forms of PrP, which may  normally be synthesized at low levels, and
which have either their C-terminus (ctmPrP, Fig. 1h) or N-terminus
(ntmPrP) in the ER lumen (Hegde et al., 1998b; Stewart and Harris,
2001). The A117V mutation has been found to result in aberrant
formation of ctmPrP (Hegde et al., 1998a). Although it was thought
that infectious PrPSc might be absent in these cases, transmission
to transgenic mice over-expressing human 117 V PrP has now been
reported, together with the identiﬁcation of rather labile PrPSc in
brain extracts (Asante et al., 2013). Increased ctmPrP has been asso-
ciated with ER stress, apoptosis, and PrPSc accumulation, suggesting
that it might contribute to the pathology in other prion disorders
as well (Hegde et al., 1998a; reviewed in Shi and Dong, 2011).
Two  human mutations have been described that result in trun-
cated PrP (Y145stop and Q160stop). Both mutant proteins may
retain their signal sequence and be directed into the cytosol and
nucleus for degradation. As described above, the fragment 23–144
(with the signal sequence for secretion removed) can aggregate
and form amyloid under non-denaturing conditions, and patients
with the Y145 stop mutation show PrP amyloid deposits in cerebral
vessels (Ghetti et al., 1996; Lorenz et al., 2002).2.3. PrPC cleavage product C1 and cytotoxicity
The GPI-anchored C1 fragment generated by physiological N-
terminal truncation of PrP (Section 1.2 and Fig. 1c) was  able
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o potentiate p53-dependent staurosporine-induced apoptosis in
ultured cells (Sunyach et al., 2007). However, C1 appears to
e abundant, both in normal human brain and on human neu-
oblastoma cells (Chen et al., 1995), and mice expressing a
ransgene encoding C1 in the absence of wild type PrP remained
ealthy and were resistant to prion disease (Westergard et al.,
011).
.4. Cytosolic PrPC aggregates and PrP misfolding
Intracellular PrP aggregates have been described in cases of
poradic CJD and familial Gerstmann–Sträussler–Scheinker dis-
ase (Aidt et al., 2013; Kovacs et al., 2005). Experimentally,
rolonged ER stress, proteasome inhibition or overexpression of
 cytosolic form of PrP that lacks signal sequences can result
n the formation of cytosolic PrP aggregates. These are distinct
rom PrPSc, but share some characteristics, including partial insol-
bility in non-ionic detergents and resistance to proteinase K
Drisaldi et al., 2003; Ma  and Lindquist, 2002; Yedidia et al.,
001), and this PrPC forms PrPSc more readily in a cell-free con-
ersion system (Hetz et al., 2007). Aggregated cytosolic PrP has
een found to compromise cell viability, or to increase sensitiv-
ty to staurosporine-induced apoptosis (Grenier et al., 2006; Ma
nd Lindquist, 2001), and transgenic mice expressing secretion-
eﬁcient PrP developed a neurological illness involving cerebellar
euronal death and gliosis (Ma  et al., 2002). Small increases in
he amount of PrP re-routed into the cytosol by pre-emptive qual-
ty control were also sufﬁcient to cause (mild) neurodegeneration
Rane et al., 2008), suggesting that this mechanism might con-
ribute to the pathology in prion disease. Interestingly, ER stress
an result from prion infection (reviewed in Hetz and Soto, 2006),
nd the unfolded protein response (UPR), an indicator of ER stress, is
n important, but relatively late response to prion infection in vivo
Moreno et al., 2012) (but see also Unterberger et al., 2006) (see
ection 4.3).
.5. PrPC in cancer
PrPC is expressed in many normal tissues and is up-regulated in
any tumours, including breast, gastric, colorectal carcinoma, pan-
reatic ductal adenocarcinoma and astrocytoma. Several different
orms of PrP have been implicated in cancers. In breast cancer cell
ines, cell surface PrP (Fig. 1b) has been found to up-regulate and
ind to the drug pump, P-glycoprotein, which is associated with
ultidrug resistance and cell survival (Li et al., 2009b). In colon
ancer cells, cell surface PrPC was found to be associated with prolif-
ration, cell survival, and drug insensitivity by antibody inhibition
xperiments (McEwan et al., 2009). It was also revealed as a candi-
ate biomarker for colorectal adenoma-to-carcinoma progression
y cell surface proteomics (de Wit  et al., 2012).
In pancreatic ductal adenocarcinoma and melanoma, an ung-
ycosylated form of PrPC has been detected, in which the signal
equence for the GPI anchor is thought to span the plasma mem-
rane (Li et al., 2009a) (Fig. 1i). This transmembrane form of PrP
inds the cytoskeletal protein, ﬁlamin A, which links cell sur-
ace receptors to the actin cytoskeleton, and plays important roles
n proliferation, survival and cell adhesion (Li et al., 2010; Sy
t al., 2010). Interestingly, it has been observed that the PrP sig-
al sequence for the GPI anchor has evolved from a bona ﬁde
embrane-spanning sequence (Schmitt-Ulms et al., 2009), which
xplains its propensity to revert to this phenotype.
ER stress can induce the appearance of PrP in the cytosolSections 1.3 and 2.4) and is a feature of many cancers. Fur-
hermore, hypoxia, which often develops in solid tumours, was
hown to induce increasing levels of cytosolic PrP in gastric can-
er cell lines (Liang et al., 2007). Cytoplasmic PrP has now beenrch 207 (2015) 136–145
described in many types of tumour, including breast, colorectal
and gastric tumours, where it is associated with poor prognosis
(Antonacopoulou et al., 2010; Dery et al., 2013; Du et al., 2005).
The anti-apoptotic effects of cytosolic PrPC described in Section 1.3
have been shown to protect a breast cancer cell line against Bax-
mediated apoptosis (Lin et al., 2008; Roucou et al., 2005). PrP was
also able to delay ER stress-induced apoptosis in breast cancer cell
lines (Dery et al., 2013), although it is not clear which form of PrP
was active in these experiments. Clearly a combination of factors
may  inﬂuence which pathways are activated in a particular cell
type.
3. PrPSc – in health?
Prion-like protein states, stably heritable at the cellular level,
are now associated with a number of neurodegenerative diseases,
including Alzheimer’s disease and Parkinson’s disease (reviewed
in Polymenidou and Cleveland, 2012; Prusiner, 2012), but may
also have normal functions. Several cytosolic yeast proteins have
cell autonomous, heritable prion forms, which can be beneﬁcial
under certain conditions, such as nutrient deﬁciency (Liebman and
Chernoff, 2012). An active, amyloidogenic and dominantly self-
perpetuating form of cytoplasmic polyadenylation element binding
protein (CPEB) might play a role in persistent synaptic facilitation
in sensory neurons of the sea slug, Aplysia (Si et al., 2010). Fur-
thermore, many peptide and protein hormones may be stored in
secretory granules of mammalian endocrine cells in an amyloid-
like state (Maji et al., 2009).
Given its involvement in the pathology of the prion dis-
eases it is unlikely that PrPSc has a cellular function, but single
nucleotide polymorphisms in the human gene for PrP have been
associated with differences in long term memory in healthy
young adults (Papassotiropoulos et al., 2005), and aggregated,
non-infectious states have been shown for PrP by numerous inves-
tigators (Baskakov and Breydo, 2007).
4. PrPSc – in sickness
4.1. PrPSc – infectious conformers
PrPSc is the cause of infectious prion disease. It has a substan-
tially higher  sheet content than PrPC, a pronounced propensity
to aggregate, and it is able to replicate by binding to PrPC and
refolding it into the PrPSc conformation. Only about 1% of human
prion disease is caused by infection from an external source. Most
prion disease is sporadic, and it is not clear what initiates forma-
tion of PrPSc in these cases. However, when PrPSc is available to
competent cells, it may  ‘replicate’ and spread, causing neurode-
generation (reviewed in Colby and Prusiner, 2011). The conversion
process probably occurs predominantly either on the cell surface
or in an endocytic compartment (Godsave et al., 2013; Goold et al.,
2011; Marijanovic et al., 2009; Rouvinski et al., 2014), in membrane
‘rafts’ (Campana et al., 2005). The GPI anchor and membrane ‘raft’
components also appear to play an important role in PrPC to PrPSc
conversion in a cell-free prion ampliﬁcation system (Abid et al.,
2010; Kim et al., 2009).
PrPSc is normally full length at conversion but it may  subse-
quently undergo beta cleavage at around amino acid 90 to give a
soluble N2 fragment and a GPI-anchored, variably glycosylated C2
fragment, which runs on SDS polyacrylamide gels as several bands
of 27–30 kDa (reviewed in Altmeppen et al., 2012). The glycosyla-
tion of PrP is known to create substantial size heterogeneity (Turk
et al., 1988), with the mono- and di-glycosylated forms of PrP 27–30
migrating at ∼27 and 30 kDa, respectively. The mobility of the un-
glycosylated peptide is higher, resulting in an SDS PAGE band at
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19 kDa. By contrast to the beta cleavage of PrPC, the N-terminal
runcation of PrPSc is thought to occur in lysosomes (Caughey et al.,
991).
Both full length PrPSc and the N-terminally truncated C2 frag-
ent exist as infectious aggregates, and in brain extracts these
ay  vary in size from small oligomers to ﬁbrils and rods and
igh molecular weight amyloid (Tzaban et al., 2002). PrPSc was
riginally distinguished from PrPC by its insolubility in detergents
nd the resistance of its C-terminal core to proteinase K. The pro-
ease resistance of large PrPSc aggregates is generally higher than
maller, oligomeric PrPSc, and it is now clear that proteinase K-
ensitive oligomers represent a high proportion of the PrPSc in
ome forms of prion disease, and they also support PrPC to PrPSc
onversion (Pastrana et al., 2006; Safar et al., 1998; Tzaban et al.,
002). Oligomeric PrPSc may  in fact be more infectious than larger
olymers (Silveira et al., 2005).
.2. Species barrier and strains
PrPC to PrPSc conversion is thought to be a template-assisted
rocess, and transmission of prion disease depends on the amino
cid sequences of the host PrPC and the infectious PrPSc, the tertiary
onformation of the PrPSc and the route of transmission. Sequence
dentity of host PrPC and inoculated PrPSc is important for efﬁcient
nfection. Species differences generally cause a failure to infect,
nfection that remains sub-clinical, or a very long incubation time
o disease. ‘Species barriers’ may  often be overcome by serial pas-
aging through the host species, leading to higher rates of attack
nd shortening incubation times (Beringue et al., 2008).
PrPSc with the same protein sequence can exist in different phe-
otypic strains, which have different biochemical characteristics
nd different levels of infectivity, and which can produce prion dis-
ases that follow distinct courses (reviewed in Colby and Prusiner,
011; Morales et al., 2007). The basis for this phenomenon is con-
idered to be heritable variations in conformation, which can be
etected as differences in sensitivity to proteinase K, in distinct
ragments generated by partial proteolysis, relative ease of dena-
uration, and glycotype ratio. In mice, prion strains with relatively
nstable PrPSc generally cause more rapidly progressing disease.
his may  be because they are more likely to fragment into smaller
rPSc multimers, presenting more sites for PrPC binding and con-
ersion (Legname et al., 2006). Less stable PrPSc aggregates also
nvaded the CNS more efﬁciently (Bett et al., 2012). By contrast, efﬁ-
iency of replication seemed to play a greater role in determining
ncubation periods in a hamster study (Ayers et al., 2011) (discussed
n Safar, 2012; Solforosi et al., 2013).
Generally, when prion replication occurs in a new host species,
he characteristics of the donor strain are maintained. However, if
 very high species barrier is overcome by serial passaging, a new
train may  be produced, possibly by selection of a strain that was
resent as a minor component of the inoculum (Beringue et al.,
008; Wickner et al., 2009).
PrP polymorphisms can strongly inﬂuence susceptibility to
rion disease, as is the case for genetic prion disease. Homozygosity
t residue 129 of human PrP is a susceptibility factor to infectious
nd sporadic prion disease, and, to date, all clinical cases of vari-
nt CJD caused by exposure to bovine spongiform encephalopathy
BSE) prions have been homozygous for methionine at this posi-
ion (reviewed in Wadsworth and Collinge, 2007). Most natural
rion transmission probably occurs via an oral route, with prions
eplicating in the lymphoid tissues before invading the central ner-
ous system (reviewed in Mabbott and MacPherson, 2006). This
s generally much less efﬁcient than direct inoculation into the
rain (reviewed in Beringue et al., 2008). However, it was  recently
eported that BSE prions replicate more efﬁciently in the spleensrch 207 (2015) 136–145 141
of humanised transgenic mice than in the brain (Beringue et al.,
2012).
4.3. PrPSc and pathology
PrPSc accumulation is the ﬁrst sign of prion disease in mice inoc-
ulated intracerebrally with prions. In hippocampus, several studies
have demonstrated an early loss of synaptic activity and a gradual
increase in reactive astrocytes and microglia (Cunningham et al.,
2003; Franklin et al., 2008; Jeffrey et al., 2000; Tamgüney et al.,
2009). Functional abnormalities of mitochondria have also been
found at an early stage (Siskova et al., 2010). The loss of synaptic
components is followed by axon terminal degeneration and then
dendritic atrophy (Gray et al., 2009). Motivational behaviours are
the ﬁrst to be affected (Chiti et al., 2006), and the change coincides
with activation of the unfolded protein response and translational
repression (Moreno et al., 2012). Cell death, autophagy, spongiform
change and abnormal motor activity are late events (Sikorska et al.,
2007; Williams et al., 1997), with terminal disease also occurring
in prion-infected mice lacking either caspase 12 or Bax expression
(Steele et al., 2007a,b).
In prion-infected mouse neuroblastoma cells, recently formed
PrPSc can be recognized by the presence of the N-terminal domain,
which is cleaved off shortly after conversion. In these cells full-
length PrPSc is found mainly on the cell surface (Rouvinski et al.,
2014). Also in RML  prion-infected FVB mouse brains, the majority of
PrPSc is N-terminally truncated (Godsave et al., 2013). We  made use
of this observation for our cryo-immunogold EM studies of prion-
infected mouse hippocampus, reasoning that antibodies to the
N-terminus of PrP such as Saf32 should preferentially recognize full
length PrPC and recently formed PrPSc (Godsave et al., 2013). PrPC
labelling is dispersed in both uninfected and infected hippocampus
(Godsave et al., 2008). By contrast, clusters of Saf32 labelling were
observed in increasing numbers in prion-infected hippocampus,
most likely indicating sites containing recently formed PrPSc. These
were found predominantly on plasma membranes, frequently on
plasma membrane invaginations and at places of cell-to-cell con-
tact (Fig. 2), suggesting that closely apposed membranes may
provide a favourable environment for conversion and intercellular
spreading of PrPSc (Godsave et al., 2013).
Neuropathology might be caused by full length newly formed
PrPSc or by older, N-terminally truncated PrPSc, so we also per-
formed cryo-immunogold EM using antibodies to the C-terminus
of PrP. The C-terminal half of PrP is present in both full-length and
truncated PrPSc, as well as in PrPC, but conversion to PrPSc renders
many epitopes inaccessible to antibodies. However, the amino acids
225–231 close to the GPI anchor remain exposed in PrPSc, and are
recognized by the R2 antibody. R2 labelling was low in uninfected
hippocampus, and was  increased by approximately six fold by a
late pre-clinical disease phase in FVB mice infected by RML  prions,
when signiﬁcant astrocytosis was  present. Since PrPC levels do not
increase during prion infection, the increase was  attributed to PrPSc.
The biggest increases in labelling were on small diameter neurites
in the neuropil, on plasma membranes and in vesicles resem-
bling early endocytic or recycling endosomes (Godsave et al., 2008)
(Fig. 2). Immuno-EM studies using plastic-embedded brain tissues
also showed most PrPSc to be on plasma membranes, and found
PrPSc on plasma membrane invaginations (Jeffrey et al., 2011).
These were not obviously associated with signs of neurodegener-
ation, but it is likely that membrane-bound prions affect various
cellular activities. For example, in the hypothalamic-derived cell
line (GT1), conversion has been found to involve aberrant activation
and localization of components of the ERK1/2 pathway (Didonna
and Legname, 2010) and interestingly, inhibitors of the pathway
were able to clear PrPSc in GT1 cells (Nordstrom et al., 2009). The
expression of genes in this pathway was  also found to be affected
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n (late stage) prion-infected mouse brains (Sorensen et al., 2008).
he prion protein has metal binding sites and prion infection causes
etal dyshomeostasis and oxidative damage (Singh et al., 2010),
ossibly already at an early stage of prion disease in some brain
egions (Yun et al., 2006). Furthermore, prion infection has been
inked to Notch-1 activation in prion-infected cells and brains.
ctivated Notch-1 inhibits the growth and maturation of axons
nd dendrites during neuronal development, and can cause their
egression after maturation, and it has been associated with den-
ritic atrophy in prion disease (Ishikura et al., 2005 and references
herein).
As described above, a number of studies have indicated that
ynaptic transmission is affected early in prion disease (reviewed
n Mallucci, 2009). We  have seen PrP at synapses (Fig. 2), but our
wn and several other immuno-EM studies have failed to show
ny preferential localization of either PrPC or PrPSc at synapses,
nd labelling of synaptic vesicles was also relatively rare (Ersdal
t al., 2009; Godsave et al., 2008; Mironov et al., 2003). However,
ynapses are often far from the cell body and may  be affected by
ysfunctioning of more proximal support systems. Interestingly,
lustering of neuronal PrP molecules at the cell surface of cultured
rimary neurons has been found to cause synapse damage, asso-
iated with an increase in membrane cholesterol and activation of
hospholipase A2. This was dependent on the GPI anchor and was
ediated speciﬁcally via the GPI anchor of neuronal PrP (Bate and
illiams, 2012).
Neurons exhibit the highest levels of PrPC, and transgenic mice
xpressing PrP speciﬁcally on neurons are highly susceptible to
nfection by intracerebrally inoculated prions (Race et al., 1995).
owever, prion infection can occur in transgenic mice that only
xpress PrP in astrocytes, although neurodegenerative prion dis-
ase developed more slowly and required higher levels of PrPSc
Jeffrey et al., 2004; Raeber et al., 1997). PrPSc has also been
bserved on astrocyte plasma membranes and occasionally in
strocyte lysosomes, possibly reﬂecting phagocytosis (Jeffrey et al.,
011).
Plaques of amyloid ﬁlaments are present to different extents in
ifferent types of prion disease and it has been proposed that amy-
oid formation may  be a mechanism for sequestering away PrPSc
Caughey and Lansbury, 2003). We  have not detected amyloid in
ML  prion-infected mouse hippocampus (Godsave et al., 2008).
. Concluding remarks
PrPC exists in a variety of shapes and sizes and can hitch up with
ifferent binding partners to inﬂuence many cellular processes,
ncluding response to oxidative stress and ER stress, proliferation
nd apoptosis. PrPC can be neuroprotective, but it is also essen-
ial for the neurotoxicity of PrPSc and possibly also of oligomers
f amyloid . Much progress has been made, but the involvement
f different PrP forms in these processes in vitro and especially in
ivo, as well as their binding partners and regulation, still need to
e better understood.
It is likely that the folding of mammalian proteins into prion-
ike conformations is not always disease-related. It may  also be a
echanism for storing proteins or regulating their activity. This is
n interesting area for further study and may  help in understanding
he initial refolding to the prion form in sporadic prion diseases.
Many pathological changes have been described in prion-
iseased brains, but we need to know more about the cellular
vents that follow prion replication and how these are linked to
ynaptic dysfunction and behavioural changes. There are probably
echanisms in common between prion diseases and the prion-like
iseases, such as Alzheimer’s disease, and much to gain by sharing
nformation and resources.rch 207 (2015) 136–145
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